Review on the management of cardiovascular risk factors in the elderly

[1]

Robles González E. What are the main causes of death of the oldest-old in Spain. Estudios Geográficos 2009; 70: 567−598.

[2]

Salazar E, Lasses LA. Patología cardiovascular en el anciano. Cardiovascular disease in the elderly. Arch Cardiol Mex 2001; 71: 109−113.

[3]

Sánchez RG, Novella Arribas B, Alonso Arroyo M, et al. The EPICARDIAN project, a cohort study on cardiovascular diseases and risk factors among the elderly in Spain: methodological aspects and major demographic findings. Rev Esp Salud Publica 2004; 78(2): 243−255.

[4] Díez-Villanueva P, Arizá-Solé A, Vidán MT, et al. Recommendations of the Geriatric Cardiology Section of the Spanish Society of Cardiology for the Assessment of Frailty in Elderly Patients With Heart Disease. Rev Esp Cardiol (Engl Ed) 2019; 72: 63−71. doi: 10.1016/j.recesp.2018.06.015 [5] Aguayo-Albasini JL, Flores-Pastor B, Soria-Aledo V. GRADE system: classification of quality of evidence and strength of recommendation. Cir Esp 2014; 92: 82−88. doi: 10.1016/j.ciresp.2013.08.002 [6] León-Muñoz LM, Martínez-Gómez D, Balboa-Castillo T, et al. Continued sedentariness, change in sitting time, and mortality in older adults. Med Sci Sports Exerc 2013; 45: 1501−1507. doi: 10.1249/MSS.0b013e3182897e87 [7] Shibata A, Oka K, Ishii K, et al. Objectively assessed patterns and reported domains of sedentary behavior among japanese older adults. J Epidemiol 2019; 29: 334−339. doi: 10.2188/jea.JE20180041 [8]

Figueiró TH, Arins GCB, Santos CESD, et al. Association of objectively measured sedentary behavior and physical activity with cardiometabolic risk markers in older adults. PLoS One. 2019; 14: e0210861.

[9] Sandbakk SB, Nauman J, Zisko N, et al. Sedentary time, cardiorespiratory fitness, and cardiovascular risk factor clustering in older adults-the generation 100 study. Mayo Clin Proc 2016; 91: 1525−1534. doi: 10.1016/j.mayocp.2016.07.020 [10] Witham MD, Chawner M, Biase S, et al. Content of exercise programmes targeting older people with sarcopenia or frailty - findings from a UK survey. J Frailty Sarcopenia Falls 2020; 5: 17−23. doi: 10.22540/JFSF-05-017 [11]

Swartz AM, Cho CC, Welch WA, et al. Pattern analysis of sedentary behavior change after a walking intervention. Am J Health Behav 2018; 42: 90−101.

[12] Barengo NC, Antikainen R, Harald K, et al. Smoking and cancer, cardiovascular and total mortality among older adults: The Finrisk Study. Prev Med Rep 2019; 14: 100875. doi: 10.1016/j.pmedr.2019.100875 [13]

Burns DM. Cigarette Smoking Among the Elderly: Disease Consequences and the Benefits of Cessation. Am J Health Promot 2000; 14: 357−361.

[14] Taylor DH Jr, Hasselblad V, Henley SJ, et al. Benefits of smoking cessation for longevity. Am J Public Health 2002; 92: 990−996. doi: 10.2105/AJPH.92.6.990 [15] Peters R, Poulter R, Warner J, et al. Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr 2008; 8: 36. doi: 10.1186/1471-2318-8-36 [16] Mons U, Schöttker B, Müller H, et al. History of lifetime smoking, smoking cessation and cognitive function in the elderly population. Eur J Epidemiol 2013; 28(10): 823−831. doi: 10.1007/s10654-013-9840-9 [17] Choi W, Kim SH, Kang SH, et al. Differential impact of smoking on cardiac or non-cardiac death according to age. PLoS One 2019; 14: e0224486. doi: 10.1371/journal.pone.0224486 [18]

Gellert C, Schöttker B, Brenner H. Smoking and all-cause mortality in older people: systematic review and meta-analysis. Arch Intern Med 2012; 172: 837−844.

[19] Mons U, Müezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ 2015; 350: h1551. doi: 10.1136/bmj.h1551 [20] Pujades-Rodriguez M, George J, Dinesh Shah A, et al. Heterogeneous associations between smoking and a wide range of initial presentations of cardiovascular disease in 1 937 360 people in England: lifetime risks and implications for risk prediction. Int J Epidemiol 2015; 44: 129−141. doi: 10.1093/ije/dyu218 [21]

Orleans CT, Boyd NR, Noll E, et al. Computer tailored intervention for older smokers using transdermal nicotine. Tob Control 2000; 9(Suppl 1): I53.

[22] Ossip-Klein DJ, Carosella AM, Krusch DM. Self-help interventions for older smokers. Tob Control 1997; 6: 188−193. doi: 10.1136/tc.6.3.188 [23] Rimer BK, Orleans CT, Fleisher L, et al. Does tailoring matter? The impact of a tailored guide on ratings and short-term smoking-related outcomes for older smokers. Health Educ Res 1994; 9: 69−84. doi: 10.1093/her/9.1.69 [24] [25] Babio N, Becerra-Tomás N, Martínez-González MÁ, et al. Consumption of yogurt, low-fat milk, and other low-fat dairy products is associated with lower risk of metabolic syndrome incidence in an elderly mediterranean population. J Nutr 2015; 145: 2308−2316. doi: 10.3945/jn.115.214593 [26] Dalsgaard E, Vestergaard M, Skriver MV, et al. Socioeconomic position and cardiovascular risk factors among people with screen-detected Type 2 DM: six-year follow-up of the ADDITION-Denmark trial. Prim Care Diabetes 2014; 8: 322−339. doi: 10.1016/j.pcd.2014.01.006 [27] Ahmadi S, Streja E, Zahmatkesh G, et al. Reverse epidemiology of traditional cardiovascular risk factors in the geriatric population. J Am Med Dir Assoc 2015; 16: 933−939. doi: 10.1016/j.jamda.2015.07.014 [28] Babio N, Toledo E, Estruch R, et al. Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial. CMAJ 2014; 186: E649−E657. doi: 10.1503/cmaj.140764 [29] Del Pinto R, Ferri C. Hypertension management at older age: an update. High Blood Press Cardiovasc Prev 2019; 26: 27−36. doi: 10.1007/s40292-018-0290-z [30] [31] Aprahamian I, Sassaki E, Dos Santos MF, et al. Hypertension and frailty in older adults. J Clin Hypertens 2018; 20: 186−192. doi: 10.1111/jch.13135 [32]

Musini VM, Tejani AM, Bassett K, et al. Pharmacotherapy for hypertension in adults 60 years or older. Cochrane Database Syst Rev 2019; 6: CD000028.

[33] Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 - benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials. J Hypertens 2018; 36: 1622−1636. doi: 10.1097/HJH.0000000000001787 [34]

Garrison SR, Kolber MR, Korownyk CS, et al. Blood pressure targets for hypertension in older adults. Cochrane Database Syst Rev 2017; 8: CD011575.

[35] Moraes AAI, Baena CP, Muka T, et al. Achieved systolic blood pressure in older people: a systematic review and meta-analysis. BMC Geriatr 2017; 17: 279. doi: 10.1186/s12877-017-0672-4 [36] Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years: a randomized clinical trial. JAMA 2016; 315: 2673−2782. doi: 10.1001/jama.2016.7050 [37] Bentley DC, Nguyen CH, Thomas SG. Resting blood pressure reductions following handgrip exercise training and the impact of age and sex: a systematic review and narrative synthesis. Syst Rev 2018; 7: 229. doi: 10.1186/s13643-018-0876-5 [38]

Rodriguez-Mañas L, Laosa O, Vellas B, et al. European MID-Frail Consortium. Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus. J Cachexia Sarcopenia Muscle 2019; 10: 721−733.

[39]

Miller ME, Williamson JD, Gerstein HC, et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial Diabetes Care 2014; 37: 634-643.

[40] Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560−2572. doi: 10.1056/NEJMoa0802987 [41]

Araki A, Limuro S, Sakurai T, et al. Long-term multiple risk factor interventions in Japanese elderly diabetic patients: the Japanese Elderly Diabetes Intervention Trial-study design, baseline characteristics and effects of intervention. Geriatr Gerontol Int 2012; 12(Suppl 1): 7−17.

[42] Hamada S, Gulliford MC. Mortality in individuals aged 80 and older with type 2 diabetes mellitus in relation to glycosylated hemoglobin, blood pressure, and total cholesterol. J Am Geriatr Soc 2016; 64: 1425−1431. doi: 10.1111/jgs.14215 [43] Yau CK, Eng C, Cenzer IS, et al. Glycosylated hemoglobin and functional decline in community-dwelling nursing home-eligible elderly adults with diabetes mellitus. J Am Geriatr Soc 2012; 60: 1215−1221. doi: 10.1111/j.1532-5415.2012.04041.x [44] Yanagita I, Fujihara Y, Eda T, et al. Low glycated hemoglobin level is associated with severity of frailty in Japanese elderly diabetes patients. J Diabetes Investig 2018; 9: 419−425. doi: 10.1111/jdi.12698 [45] Zaslavsky O, Walker RL, Crane PK, et al. Glucose levels and risk of frailty. J Gerontol A Biol Sci Med Sci 2016; 71: 1223−1229. doi: 10.1093/gerona/glw024 [46] Nelson JM, Dufraux K, Cook PF. The relationship between glycemic control and falls in older adults. J Am Geriatr Soc 2007; 55(12): 2041−2044. doi: 10.1111/j.1532-5415.2007.01430.x [47]

Schwartz AV, Vittinghoff E, Sellmeyer DE, et al. Health, aging, and body composition study. diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care 2008; 31(3): 391−396. Erratum in: Diabetes Care 2008; 31: 1089.

[48]

Gómez-Huelgas R, Gómez Peralta F, Rodríguez Mañas L, et al. Treatment of type 2 diabetes mellitus in elderly patients. Rev Esp Geriatr Gerontol 2018; 53: 89−99.

[49] Robinson JG, Jayanna MB, Bairey Merz CN, Stone NJ. Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl. PLoS One 2020; 15: e0240166. doi: 10.1371/journal.pone.0240166 [50] Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 2020; 396: 1637−1643. doi: 10.1016/S0140-6736(20)32332-1 [51] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111−188. doi: 10.1093/eurheartj/ehz455 [52] Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019; 393: 407−415. doi: 10.1016/S0140-6736(18)31942-1 [53] [54] O'Connell H, Chin AV, Cunningham C, Lawlor B. Alcohol use disorders in elderly people-redefining an age-old problem in old age. BMJ 2003; 327: 664−667. doi: 10.1136/bmj.327.7416.664 [55] Haighton C, Wilson G, Ling J, et al. A qualitative study of service provision for alcohol related health issues in mid to later life. PLoS One 2016; 11: e0148601. doi: 10.1371/journal.pone.0148601 [56]

Blow FC, Brower KJ, Schulenberg JE, et al. The Michigan Alcoholism Screening Test-geriatric version (MAST-G): a new elderly-specific screening instrument. Alcohol Clin Exp Res 1992; 16: 372−374.

[57] León-Muñoz LM, Galán I, Donado-Campos J, et al. Patterns of alcohol consumption in the older population of Spain, 2008-2010. J Acad Nutr Diet 2015; 115: 213−224. doi: 10.1016/j.jand.2014.08.017 [58] Ferreira MP, Weems MK. Alcohol consumption by aging adults in the United States: health benefits and detriments. J Am Diet Assoc 2008; 108: 1668−1676. doi: 10.1016/j.jada.2008.07.011 [59] Kalla A, Figueredo VM. Alcohol and cardiovascular disease in the geriatric population. Clin Cardiol 2017; 40: 444−449. doi: 10.1002/clc.22681 [60] Perissinotto E, Buja A, Maggi S, et al. Alcohol consumption and cardiovascular risk factors in older lifelong wine drinkers: the Italian Longitudinal Study on Aging. Nutr Metab Cardiovasc Dis 2010; 20: 647−655. doi: 10.1016/j.numecd.2009.05.014 [61] Djoussé L, Biggs ML, Mukamal KJ, Siscovick DS. Alcohol consumption and type 2 diabetes among older adults: the Cardiovascular Health Study. Obesity (Silver Spring) 2007; 15: 1758−1765. doi: 10.1038/oby.2007.209 [62]

Veronese N. Frailty as Cardiovascular Risk Factor (and Vice Versa). Adv Exp Med Biol 2020; 1216: 51−54.

[63] Crome P, Cherubini A, Oristrell J. The PREDICT (increasing the participation of the elderly in clinical trials) study: the charter and beyond. Expert Rev Clin Pharmacol 2014; 7: 457−468. doi: 10.1586/17512433.2014.922864 [64] Aldea-Perona AM, García Saiz MDM, Fernandez Quintana E, et al. Utilidad de la ficha técnica de los medicamentos como herramienta para mejorar la prescripción en pacientes mayores. Rev Esp Geriatr Gerontol 2020; 55: 156−159. doi: 10.1016/j.regg.2020.01.002

留言 (0)

沒有登入
gif